CellProtect
Sponsors
Karolinska Institutet, Karolinska Institutet, Karolinska Institutet
Conditions
Multiple MyelomaMultiple myeloma
Phase 2
Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
RecruitingNCT04558931
Start: 2021-06-02End: 2032-12-31Target: 62Updated: 2023-10-11
An open, randomised, controlled phase II trial of CellProtect in combination with Isatuximab antibody versus Isatuximab antibody alone as maintenance treatment in patients with Multiple Myeloma undergoing high dose treatment (ISA-HC-NK)
Active, not recruitingCTIS2024-514527-42-00
Start: 2023-07-28Target: 62Updated: 2024-09-26